Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5713-5714-5715 in Seasonal Allergic Rhinitis
NCT04709575Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of REGN5713, bremzalerbart, atisnolerbart in seasonal allergic rhinitis (SAR), allergic conjunctivitis (AC), sponsored by Regeneron Pharmaceuticals. Started Jan 2021; status: completed.
02
Drugs
REGN5713bremzalerbartatisnolerbart
03
Conditions
seasonal allergic rhinitis (SAR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT04709575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709575.